ArticleCancers2022

Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Koji Iinuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.